{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Lenvatinib vs. Sorafenib as First-Line Treatment for Unresectable HCC
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Purpose of Activity
To provide information on the use of lenvatinib as first-line treatment and other, second-line treatments, for unresectable hepatocellular carcinoma (HCC).Learning Objectives
After completing this continuing education activity you will be able to:
- Propose encouraging second-line treatments for HCC patients having prior sorafenib therapy.
- Appraise the results of the phase 3 evaluation of lenvatinib vs. sorafenib as first-line treatment for unresectable HCC.
Disclosures
The author, faculty, staff, and planners, including spouses/partners (if any), in any position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity.
Price:
$12.95
Credits:
- ANCC 1.0 CH
- DC - BON 1.0 CH
- KY-BON 1.0 CH
- GA - BON 1.0 CH
Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT1218
Published: Dec 2018
Expires: 12/31/2026
Sources:
Oncology Times
Required Passing Score: 7/10 (70%)
Specialties:
Oncology